Summary & Overview
HCPCS Level II J1742: Injection, Ibutilide Fumarate, 1 mg
HCPCS Level II code J1742 denotes the intravenous injection of ibutilide fumarate, 1 mg, an antiarrhythmic used for acute chemical cardioversion of recent-onset atrial flutter and atrial fibrillation. Nationally, this code matters for acute cardiac care billing and for hospitals and emergency departments that administer IV antiarrhythmic therapy. Accurate coding affects clinical documentation, claim adjudication, and aggregate utilization measures for cardiac rhythm management.
Primary payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication covers payer coverage patterns, coding benchmarks, and clinical context to inform revenue cycle and clinical teams about typical use cases and billing considerations.
Readers will find a concise overview of the clinical indication and typical settings for administration, payer coverage scope, common modifiers in use, and what is known about related coding considerations. The piece also highlights areas where policy updates or payer-specific rules commonly affect reimbursement and documentation workflows. Specific data elements not provided in the input are noted as unavailable.
Billing Code Overview
HCPCS Level II code J1742 represents an injection of ibutilide fumarate, 1 mg. This code is used to bill for the intravenous administration of ibutilide, an antiarrhythmic medication indicated for the acute conversion of recent onset atrial flutter and atrial fibrillation.
-
Service type: Intravenous antiarrhythmic medication administration
-
Typical site of service: Hospital inpatient or hospital outpatient clinic, emergency department, or monitored setting where intravenous cardiac medications are administered (e.g., telemetry unit)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult admitted to an inpatient cardiology unit or presenting to an emergency department with symptomatic atrial flutter or recent-onset atrial fibrillation requiring pharmacologic cardioversion. The patient often has hemodynamically stable palpitations, dizziness, or shortness of breath and has been evaluated with a 12-lead ECG showing atrial fibrillation or atrial flutter. Prior to administration, clinicians obtain informed consent, review electrolytes and baseline QT interval, discontinue concomitant QT-prolonging medications when appropriate, and ensure continuous cardiac monitoring and IV access. A pharmacy or nursing team prepares the J1742 product (ibutilide fumarate, 1 mg vials); dosing is weight-independent for standard adult protocols (commonly 1 mg IV over 10 minutes, may repeat once). After infusion the patient remains on telemetry with serial ECGs and monitoring for proarrhythmia (torsades de pointes), hypotension, or other adverse events. Documentation includes indication, dose, route, start/stop times, monitoring, and response (conversion to sinus rhythm or continued atrial arrhythmia). Typical sites of service are the inpatient ward, intensive care unit, emergency department, and hospital observation units where continuous monitoring is available.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Original procedure; standard professional service |